Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency (Q86052): Difference between revisions

From determinar.ia.br - Determine suas informações
‎Created a new Item
 
‎Changed label, description and/or aliases in pt-br, en
description / pt-brdescription / pt-br
 
A distrofia muscular de cinturas autossômica recessiva r (LGMD) tipo 2D pertence ao grupo dos LGMD, que são distúrbios de fraqueza muscular progressiva geneticamente determinados, nos quais a musculatura pélvica ou da cintura escapular está predominantemente ou principalmente envolvida. LGMD2D é uma sarcoglicanopatia caracterizada por asa escapular e hipertrofia da panturrilha com envolvimento cardíaco em cerca de 20% dos casos.
description / endescription / en
 
Autosomal recessive limb-girdle muscular dystrophy (LGMD) type 2D belongs to the group of LGMD, that are genetically determined, progressive muscle weakness disorders, in which the pelvic or shoulder girdle musculature is predominantly or primarily involved. LGMD2D is a sarcoglycanopathy characterised by scapular winging and calf hypertrophy with cardiac involvement in about 20% of cases.

Revision as of 11:24, 15 August 2026

Autosomal recessive limb-girdle muscular dystrophy (LGMD) type 2D belongs to the group of LGMD, that are genetically determined, progressive muscle weakness disorders, in which the pelvic or shoulder girdle musculature is predominantly or primarily involved. LGMD2D is a sarcoglycanopathy characterised by scapular winging and calf hypertrophy with cardiac involvement in about 20% of cases.
Language Label Description Also known as
default for all languages
ID_1066309170
    English
    Limb-girdle muscular dystrophy 2D, alpha-sarcoglycan deficiency
    Autosomal recessive limb-girdle muscular dystrophy (LGMD) type 2D belongs to the group of LGMD, that are genetically determined, progressive muscle weakness disorders, in which the pelvic or shoulder girdle musculature is predominantly or primarily involved. LGMD2D is a sarcoglycanopathy characterised by scapular winging and calf hypertrophy with cardiac involvement in about 20% of cases.

      Statements